Results for “inflammation”
Asthma
Asthma is a common long-term inflammatory disease of the airways. It is characterized by variable and recurring symptoms and reduced lung function. Symptoms include episodes of wheezing, coughing, chest tightness, and shortness of breath. A sudden wo
Health & MedicinePleurisy
Pleurisy is an inflammatory condition characterized by the swelling of the pleurae, the membranes surrounding the lungs and lining the chest cavity, leading to sharp chest pain and other symptoms.
Health & MedicinePaleo Diet
The **Paleo diet**, also known as the caveman diet or Stone Age diet, is a modern dietary approach that focuses on consuming foods that were likely eaten by humans during the Paleolithic era, with the goal of promoting overall health and well-being.
Economics & BusinessAstraZeneca
AstraZeneca plc is a multinational pharmaceutical and biotechnology company with a diverse portfolio of products for major diseases, operating globally with its headquarters in Cambridge, UK. ## Overview AstraZeneca plc, commonly referred to as AstraZeneca, is a Swedish-British multinational pharmaceutical and biotechnology company that has become a leading player in the global healthcare industry. Founded through the merger of two prominent companies, Astra AB and Zeneca Group, the company has a rich history of innovation and dedication to improving human health. AstraZeneca's mission is to push the boundaries of science to deliver life-changing medicines to patients worldwide. The company's diverse portfolio of products addresses major diseases in various therapeutic areas, including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. AstraZeneca's commitment to innovation is evident in its extensive research and development (R&D) efforts. The company invests heavily in R&D, collaborating with academic institutions, biotechnology companies, and other partners to advance medical science and develop new treatments. AstraZeneca's global presence, with operations in over 100 countries, enables the company to reach patients worldwide and address the diverse healthcare needs of different regions. ## History/Background AstraZeneca's history dates back to the 19th century, when Astra AB was founded in Sweden in 1913. The company's early focus was on developing medicines for infectious diseases, and it quickly gained a reputation for innovation and quality. In the 1990s, Astra AB merged with Zeneca Group, a British pharmaceutical company, to form AstraZeneca. The merger created a global pharmaceutical leader with a diverse portfolio of products and a strong presence in the industry. Throughout its history, AstraZeneca has been at the forefront of medical innovation, developing several groundbreaking treatments that have improved the lives of millions of patients worldwide. The company's commitment to R&D has led to numerous breakthroughs, including the development of the first triple combination therapy for HIV/AIDS and the first treatment for certain types of lung cancer. ## Key Information AstraZeneca's portfolio of products includes a range of medicines for major diseases in various therapeutic areas. Some of the company's most notable products include: * **Lynparza**: a PARP inhibitor for the treatment of ovarian cancer and breast cancer * **Tagrisso**: a targeted therapy for the treatment of non-small cell lung cancer * **Farxiga**: a sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes * **Brilinta**: an antiplatelet agent for the prevention of cardiovascular events AstraZeneca has a strong track record of innovation, with a pipeline of promising new medicines in development. The company's commitment to R&D has led to numerous partnerships and collaborations with academic institutions, biotechnology companies, and other partners. ## Significance AstraZeneca's significance extends beyond its role as a global pharmaceutical leader. The company's commitment to innovation and R&D has led to numerous breakthroughs in medical science, improving the lives of millions of patients worldwide. AstraZeneca's global presence and diverse portfolio of products enable the company to address the diverse healthcare needs of different regions, making it a vital partner in the global healthcare industry. INFOBOX: - Name: AstraZeneca plc - Type: Multinational pharmaceutical and biotechnology company - Date: Founded in 1999 (merger of Astra AB and Zeneca Group) - Location: Cambridge, UK (headquarters) - Known For: Development of groundbreaking treatments for major diseases, including cancer, cardiovascular disease, and diabetes TAGS: AstraZeneca, pharmaceutical company, biotechnology, oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, inflammation, R&D, innovation, medical science, healthcare industry.
Health & MedicineOmega-3 Fatty Acids
** Omega‑3 fatty acids are essential polyunsaturated fats that support cardiovascular, neurological, and inflammatory health, and must be obtained from diet or supplements. **CONTENT:** ## Overview Omega‑3 fatty acids are a family of **polyunsaturated fatty acids (PUFAs)** distinguished by the presence of a double bond three carbon atoms from the methyl end of the molecule. The three most biologically active forms for humans are **eicosapentaenoic acid (EPA)**, **docosahexaenoic acid (DHA)**, and **α‑linolenic acid (ALA)**. EPA and DHA are long‑chain omega‑3s found primarily in marine sources such as fatty fish, krill, and algae, whereas ALA is a shorter‑chain plant‑derived omega‑3 present in flaxseed, chia seeds, walnuts, and canola oil. Because the human body cannot synthesize the essential ALA, and can only convert a small fraction (≈5‑10 % for EPA and <0.5 % for DHA) from ALA, dietary intake of pre‑formed EPA/DHA is recommended for optimal health. These fatty acids are incorporated into cell membranes, influencing fluidity, receptor function, and the production of **eicosanoids**, which are signaling molecules that regulate inflammation, blood clotting, and immune responses. Clinical research links adequate omega‑3 intake to reduced risk of **coronary heart disease**, lower triglyceride levels, improved cognitive function, and potential benefits in mood disorders. However, individual responses vary, and excessive supplementation can cause adverse effects such as bleeding tendencies or gastrointestinal upset. Anyone considering high‑dose omega‑3 supplements—especially those on anticoagulant therapy—should consult a health professional. ## History/Background The scientific interest in omega‑3 fatty acids began in the early 20th century when researchers observed that diets rich in fish oil prevented **beriberi‑like** symptoms in dogs. In 1929, **George and Mildred Burr** identified the “**essential fatty acid**” concept, noting that certain fats were required for normal growth. The term “omega‑3” was coined in the 1960s after **J. J. Lands** elucidated the structural importance of the third carbon‑carbon double bond. Key milestones include: - **1970s:** Danish epidemiologist **Danish Study** (the “**Danish Diet, Cancer, and Health**” cohort) linked high fish consumption with lower heart disease rates, sparking global interest. - **1979:** **J. H. Lands** demonstrated that EPA and DHA are precursors to anti‑inflammatory eicosanoids. - **1994:** The **American Heart Association** issued its first dietary recommendation for omega‑3 intake (≈1 g EPA/DHA per day for patients with coronary heart disease). - **2000s:** Large randomized trials (e.g., **GISSI‑Prevenzione**, **REDUCE‑IT**) provided mixed but generally supportive evidence for cardiovascular protection, prompting FDA approval of prescription omega‑3 formulations. Today, omega‑3 research spans nutrigenomics, mental health, and sustainable aquaculture, reflecting its broad relevance. ## Key Information - **Chemical Structure:** Omega‑3s have a **cis‑double bond** at the third carbon from the methyl end; EPA (20:5 n‑3) contains 20 carbons and 5 double bonds, DHA (22:6 n‑3) has 22 carbons and 6 double bonds, ALA (18:3 n‑3) has 18 carbons and 3 double bonds. - **Dietary Sources:** - *Marine*: salmon, mackerel, sardines, herring, anchovies, oysters, krill oil, algal oil (vegetarian DHA source). - *Plant*: flaxseed oil, chia seeds, hempseed, walnuts, soybeans, canola oil (primarily ALA). - **Recommended Intake:** - General adult population: **250–500 mg combined EPA + DHA** per day (≈2 servings of fatty fish weekly). - Specific conditions (e.g., hypertriglyceridemia): **2–4 g EPA/DHA** per day under medical supervision. - **Health Effects:** - *Cardiovascular*: ↓ triglycerides, modest ↓ systolic blood pressure, anti‑arrhythmic properties. - *Neurological*: DHA is a major structural component of brain gray matter; adequate intake supports cognition and may slow age‑related decline. - *Inflammatory*: EPA‑derived eicosanoids are less pro‑inflammatory than arachidonic‑acid derivatives, benefiting rheumatoid arthritis and asthma. - *Pregnancy*: DHA supports fetal retinal and brain development; many prenatal vitamins include 200–300 mg DHA. - **Safety & Interactions:** High doses (>3 g/day) may increase bleeding time; caution with warfarin, clopidogrel, or NSAIDs. Gastrointestinal side effects (burping, fishy aftertaste) are common with fish‑oil capsules. **When to seek professional care:** If you have a history of bleeding disorders, are pregnant or nursing, have a chronic disease (e.g., heart disease, diabetes), or plan to take high‑dose omega‑3 supplements, discuss dosing with a physician or registered dietitian. ## Significance Omega‑3 fatty acids occupy a unique niche at the intersection of nutrition, pharmacology, and public health. Their **dual role** as structural membrane components and precursors to bioactive mediators makes them a cornerstone of preventive medicine. Population‑wide recommendations to increase fish consumption have shaped dietary guidelines worldwide, influencing agricultural policy, fisheries management, and the burgeoning **sustainable algae‑based omega‑3 industry**. Beyond individual health, omega‑3 research informs **clinical practice** (e.g., prescription EPA/DHA for severe hypertriglyceridemia) and **therapeutic development** (e.g., resolvins and protectins derived from EPA/DHA are being explored as novel anti‑inflammatory drugs). The environmental dimension—balancing fish‑oil demand with oceanic ecosystems—has spurred innovations in **microalgae cultivation**, offering a plant‑based, low‑contaminant source of DHA that may reduce reliance on over‑fished stocks. In summary, omega‑3 fatty acids exemplify how a molecular nutrient can drive scientific discovery, shape public health policy, and inspire sustainable food technologies, underscoring their lasting impact on human health and the planet. **INFOBOX:** - **Name:** Omega‑3 fatty acids (n‑3 PUFAs) - **Type:** Essential polyunsaturated fatty acids - **Date:** First identified as essential (1929); term “omega‑3” popularized (1960s) - **Location:** Naturally occurring in marine and terrestrial food sources; synthesized commercially from fish, krill, and algae - **Known For:** Cardiovascular protection, neurodevelopment support, anti‑inflammatory effects **TAGS:** omega-3, polyunsaturated fatty acids, EPA, DHA, ALA, cardiovascular health, nutrition, dietary supplements, inflammation
Health & MedicinePancreatitis
** Pancreatitis is an inflammatory condition of the pancreas that can present as a sudden, severe episode (acute) or as a long‑standing, progressive disease (chronic), each with distinct symptoms, causes, and complications. **CONTENT:** ## Overview The **pancreas** is a deep‑lying, bean‑shaped organ situated behind the stomach. It serves two vital roles: an exocrine function that releases digestive enzymes (such as amylase, lipase, and proteases) into the duodenum, and an endocrine function that secretes hormones—including **insulin** and **glucagon**—into the bloodstream to regulate blood glucose. **Pancreatitis** occurs when these enzymes become activated within the pancreas itself, leading to autodigestion, inflammation, and tissue injury. Two clinical forms dominate the landscape. **Acute pancreatitis** develops rapidly, often within hours, and is characterized by intense upper‑abdominal pain that radiates to the back, nausea, vomiting, and sometimes fever. Most episodes resolve within a few days with supportive care, but severe cases can progress to necrosis, infection, or organ failure. **Chronic pancreatitis** evolves over months to years, marked by persistent pain, progressive loss of exocrine function (causing fatty stools, weight loss, and malabsorption) and endocrine failure, which may culminate in **diabetes mellitus**. While the pain patterns overlap, chronic disease is distinguished by irreversible structural changes such as fibrosis and calcifications visible on imaging. Prompt medical evaluation is essential. **If you experience sudden, severe abdominal pain, especially with vomiting or fever, seek immediate professional care**, as early intervention can prevent life‑threatening complications. ## History/Background Descriptions of pancreatic inflammation date back to ancient medical texts, but the term “pancreatitis” entered the modern lexicon in the 19th century. In 1862, French surgeon **Rene Laënnec** first linked pancreatic inflammation to abdominal pain, and by the early 1900s, physicians recognized the condition’s association with gallstones and alcohol abuse. The 1950s brought the first systematic classification of **acute** versus **chronic** forms, while the 1970s saw the introduction of the **Ranson criteria**, a scoring system to predict severity in acute cases. Advances in imaging—ultrasound in the 1970s, computed tomography (CT) in the 1980s, and magnetic resonance cholangiopancreatography (MRCP) in the 1990s—revolutionized diagnosis, allowing clinicians to visualize pancreatic edema, necrosis, and ductal obstruction with unprecedented clarity. ## Key Information - **Etiology:** The most common triggers are gallstones (≈40 % of acute cases) and chronic heavy alcohol consumption (≈30 %). Other causes include hypertriglyceridemia, certain medications, traumatic injury, infections, and genetic mutations (e.g., PRSS1, SPINK1). - **Pathophysiology:** Premature activation of digestive enzymes within acinar cells initiates a cascade of inflammation, vascular leakage, and cellular death. In chronic disease, repeated injury leads to fibrosis, calcification, and loss of both exocrine and endocrine tissue. - **Clinical Presentation:** Acute pancreatitis typically presents with sudden, severe epigastric pain radiating to the back, accompanied by nausea, vomiting, and possible fever. Chronic pancreatitis manifests with persistent pain, steatorrhea (fatty stools), weight loss, and eventually **diabetes mellitus** due to β‑cell loss. - **Diagnosis:** Laboratory tests show elevated serum amylase and lipase (often >3× normal). Imaging—abdominal ultrasound for gallstones, contrast‑enhanced CT for necrosis, and MRCP for ductal anatomy—confirms the diagnosis and assesses severity. - **Management:** Acute cases require aggressive fluid resuscitation, pain control, and bowel rest; severe forms may need intensive care, antibiotics for infected necrosis, or endoscopic/ surgical drainage. Chronic pancreatitis management focuses on pain relief, pancreatic enzyme replacement, nutritional support, and strict abstinence from alcohol and smoking. - **Complications:** Include pancreatic pseudocysts, necrotizing infection, hemorrhage, systemic inflammatory response syndrome (SIRS), **diabetes mellitus**, and malnutrition. Early recognition and multidisciplinary care reduce mortality, which remains around 5 % for mild acute disease but can exceed 30 % in severe necrotizing forms. ## Significance Pancreatitis is a leading cause of gastrointestinal hospitalization worldwide, imposing a substantial burden on health systems. Its acute form is the most common gastrointestinal reason for intensive care admission, while chronic pancreatitis contributes to long‑term disability, nutritional deficiencies, and the development of **diabetes mellitus**, a major public health challenge. Understanding risk factors—particularly modifiable ones like alcohol use and gallstone disease—has driven preventive strategies, including public health campaigns on responsible drinking and early cholecystectomy for symptomatic gallstones. Moreover, research into the molecular triggers of enzyme activation has spurred novel therapeutic avenues, such as protease inhibitors and anti‑inflammatory agents, offering hope for disease‑modifying treatments beyond supportive care. The condition’s complexity underscores the need for coordinated care among gastroenterologists, surgeons, radiologists, nutritionists, and primary‑care providers. **INFOBOX:** - Name: Pancreatitis - Type: Inflammatory disease of the pancreas (gastrointestinal) - Date: First modern description – 1862 (Rene Laënnec) - Location: Pancreas (retroperitoneal organ behind the stomach) - Known For: Acute and chronic inflammation leading to severe abdominal pain, organ dysfunction, and potential progression to diabetes mellitus **TAGS:** pancreas, inflammation, acute pancreatitis, chronic pancreatitis, gastrointestinal disease, diabetes mellitus, abdominal pain, gastroenterology
Health & MedicineOmega-6 Fatty Acids
Omega‑6 fatty acids are a family of polyunsaturated fats essential for human health, influencing inflammation, skin integrity, and cellular signaling, but must be balanced with omega‑3s to support optimal wellbeing.
Health & MedicineAppendicitis
** Appendicitis is an acute inflammation of the vermiform appendix that typically presents with abdominal pain, nausea, and fever, but can vary widely in its clinical picture. **CONTENT:** ## Overview Appendicitis is the most common cause of emergency abdominal surgery worldwide. It occurs when the narrow, finger‑shaped pouch attached to the cecum becomes obstructed—often by fecaliths, lymphoid hyperplasia, or foreign bodies—leading to bacterial overgrowth, increased intraluminal pressure, and inflammation of the **appendiceal wall**. The classic presentation includes **right lower quadrant (RLQ) pain** that often begins as a vague periumbilical ache before localizing, accompanied by **nausea, vomiting, fever, and loss of appetite**. However, up to **40 % of patients** may lack one or more of these hallmark signs, especially children, the elderly, and pregnant individuals, making diagnosis challenging. Prompt recognition is critical because an untreated inflamed appendix can progress to **perforation**, spilling infected contents into the peritoneal cavity. This can trigger **peritonitis**, a diffuse, painful inflammation of the abdominal lining, and may evolve into **sepsis**, a life‑threatening systemic response to infection. Early surgical removal (appendectomy) or, in selected cases, antibiotic therapy can prevent these severe outcomes. Anyone experiencing persistent abdominal pain, especially if it worsens or is accompanied by fever, should seek medical evaluation without delay. ## History/Background The appendix has been known since ancient times, but its pathological significance was not appreciated until the 19th century. In 1735, French surgeon **Rene Laënnec** first described a “perforated appendix” during autopsy, yet the condition remained obscure. The first successful **appendectomy** is credited to **Claudius Amyand** in 1735, who removed an inflamed appendix from an 11‑year‑old boy during an inguinal hernia repair. The procedure did not become routine until the late 1800s, when **Reginald Fitz** coined the term “appendicitis” in 1886 and advocated for early surgical intervention. The advent of **antiseptic techniques**, **anesthesia**, and later **laparoscopic surgery** in the 1980s dramatically reduced morbidity and mortality, establishing appendectomy as one of the safest and most common operations today. ## Key Information - **Epidemiology:** Appendicitis affects roughly **7 % of the population** at some point, with peak incidence between ages **10–30**. It is slightly more common in males. - **Pathophysiology:** Obstruction → bacterial overgrowth → increased pressure → ischemia → inflammation → possible perforation (usually within 48–72 hours). - **Clinical signs:** Classic **McBurney’s point tenderness**, **Rovsing’s sign**, **psoas sign**, and **Blumberg’s sign** (rebound tenderness) aid diagnosis, but reliance on imaging (ultrasound, CT) is now standard, especially in atypical cases. - **Diagnostic tools:** Abdominal **ultrasound** is preferred in children and pregnant patients; **contrast‑enhanced CT** offers >90 % sensitivity in adults. Laboratory findings often show **leukocytosis** and elevated **C‑reactive protein**. - **Management:** The gold‑standard treatment is **surgical appendectomy**, performed either **open** (via a right lower quadrant incision) or **laparoscopic** (minimally invasive). In selected uncomplicated cases, a course of **broad‑spectrum antibiotics** may be considered, though recurrence risk remains. - **Complications:** **Perforation**, **abscess formation**, **peritonitis**, **septic shock**, and **adhesive small‑bowel obstruction** are the major threats. Early intervention reduces perforation rates from >30 % to <10 %. - **Prognosis:** With timely treatment, mortality is <1 % in healthy adults; it rises to 5–10 % in the elderly or immunocompromised. Recovery after laparoscopic surgery is typically 1–2 weeks, versus 3–4 weeks for open procedures. ## Significance Appendicitis remains a cornerstone condition in emergency medicine and surgery, illustrating the importance of rapid clinical assessment, judicious use of imaging, and timely operative care. Its prevalence makes it a frequent teaching case for medical students learning abdominal examination techniques and differential diagnosis of acute abdomen. Advances such as **laparoscopic appendectomy** have not only shortened hospital stays and postoperative pain but also paved the way for minimally invasive approaches to other intra‑abdominal emergencies. Moreover, the condition underscores public health messages about **when to seek professional care**: persistent abdominal pain, especially with fever or vomiting, warrants prompt evaluation to avoid life‑threatening complications. **NOTE:** If you or someone you know experiences sudden, worsening abdominal pain, fever, or vomiting, seek medical attention immediately. Early diagnosis and treatment are essential to prevent serious outcomes. **INFOBOX:** - Name: Appendicitis (Acute Inflammation of the Vermiform Appendix) - Type: Acute Surgical Condition - Date: First described 1735; term “appendicitis” coined 1886 - Location: Typically the right lower quadrant of the abdomen (McBurney’s point) - Known For: Being the most common cause of emergency abdominal surgery and a classic example of a condition where rapid intervention prevents sepsis **TAGS:** appendicitis, acute abdomen, surgery, inflammation, peritonitis, sepsis, laparoscopic appendectomy, emergency medicine